Key Highlights
- MabCure describes itself as a development-stage Business built around monoclonal-antibody technology aimed at early cancer detection and targeted therapeutics.
- Founded in 2006, the company is a very small operation, with financial-data platforms listing only a handful of employees.
- Verifiable, recent corporate disclosures are scarce, and there is no steady cadence of material announcements, clinical readouts, or commercial milestones.
- MBCI trades near one hundredth of a cent with a Market Value in the tens of thousands of dollars, figures that are indicative rather than confirmed.
MabCure, Inc (OTC:MBCI) is the kind of obscure micro-cap that rarely surfaces outside of ticker screens, yet its focus, antibody-based early cancer detection, touches one of medicine's most sought-after goals. The reality behind MBCI is far more modest: a tiny development-stage company that has generated little verifiable news, trading over the counter at a fraction of a cent in the last closing session.
Company and Latest Development
MabCure describes itself as a development-stage business built around proprietary monoclonal-antibody technology aimed at the early detection of cancer and the creation of targeted cancer therapeutics. Founded in 2006, it is a very small operation, and financial-data platforms list only a handful of employees.
Verifiable, recent corporate disclosures are scarce; the company does not appear to have a steady cadence of material announcements, clinical readouts or commercial milestones that investors can independently confirm.
What Is Driving Attention Around MBCI?
No specific, verifiable catalyst explains recent trading. MBCI sits at a sub-penny quote with essentially no daily movement, a pattern common to dormant nano-caps where even tiny transactions can register on screens.
Any attention is a function of the extremely low price and the evergreen appeal of cancer-diagnostics keywords, not of a confirmed development. Notably, at least one data provider mislabels the company's sector, an artifact of thin coverage.
Key Numbers and Company Position
Firm financials are not reliably available. Aggregators show the shares near one hundredth of a cent with a market value in the tens of thousands of dollars, figures that should be read as indicative rather than confirmed.
There is no analyst rating and no recent audited disclosure detailing revenue, cash position or research spending. For a development-stage antibody company, the absence of verifiable trial data or Partnership announcements means there is little concrete on which to base a fundamental view.
What Could Come Next?
A meaningful catalyst would require the company to re-emerge with verifiable activity: new preclinical or clinical data on its antibody platform, a licensing deal or research partnership, fresh financing, or a return to regular financial reporting.
Corporate actions typical of nano-caps, such as Capital restructurings or reverse splits, are also possible, though none is confirmed. Until MabCure produces confirmable disclosure, the most realistic signal to watch for is simply evidence that the company is operationally active.
Risks to Watch
The risks are considerable. Sub-penny OTC shares carry extreme volatility, minimal Liquidity and wide bid-ask spreads, and the lack of current audited financials makes independent valuation difficult.
Development-stage diagnostics and therapeutics face long, expensive and uncertain paths to validation and regulatory clearance, with no guarantee of ever reaching the market. Dilution is a persistent threat for cash-poor micro-caps.
Potential in Theory, Disclosure in Practice
MabCure, Inc pairs an ambitious scientific mission, antibody-based cancer detection, with the hard reality of a dormant nano-cap that supplies little verifiable news. With MBCI trading at a fraction of a cent and no identifiable catalyst evident, the story is one of potential in theory versus disclosure in practice.
Investors tracking the ticker may want to watch for a resumption of regular SEC filings or any confirmable data on its antibody technology as the first genuine indication of renewed activity.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...